Forian Inc. Reports 50% Revenue Growth and Improved EBITDA in 2025 Financial Results

Forian Inc. Reports Strong Revenue Growth but Swings to Loss in FY2025; Board Evaluating Acquisition Proposal

Key Financial Highlights for Q4 and Full Year 2025

Q4 2025 Revenue: \$8.0 million, up 37% year-over-year
Q4 2025 Net Loss: \$(1.8) million, compared to net income of \$0.2 million in Q4 2024
Q4 2025 Adjusted EBITDA: \$(0.2) million, down from \$0.1 million in Q4 2024
Full Year 2025 Revenue: \$30.3 million, up 50% from \$20.2 million in 2024
Full Year 2025 Net Loss: \$(2.9) million, improved from \$(3.8) million in 2024
Full Year 2025 Adjusted EBITDA: \$0.8 million, up 72% from \$0.5 million in 2024
Cash, cash equivalents, and marketable securities: \$31.6 million as of December 31, 2025

Management Commentary

CEO Max Wygod emphasized the company’s ability to grow revenue, expand into new markets, and invest in its data platform while maintaining strict cost controls. He noted that the company achieved its revenue guidance target and met adjusted EBITDA margin profile goals despite industry headwinds. Key drivers included contract renewals, new clinical data partnerships, and increased adoption by pharmaceutical and biotech companies.

Business and Strategic Updates

Significant Revenue Growth: The company posted a robust 50% year-over-year growth in total revenue, driven by new contract wins and expanded market penetration, especially among life sciences clients.
Cost Management: Despite higher revenues, Forian swung to a net loss in Q4, reflecting increased investments in research & development, sales & marketing, and strategic review activities.
Improved Adjusted EBITDA: Adjusted EBITDA for the year rose 72%, suggesting better underlying profitability despite GAAP losses.
Strengthening Data Platform: The company expanded its clinical data feeds and partnerships, enhancing its data foundation and product offerings.
Corporate Development – Potential Buyout: On August 25, 2025, a consortium led by Forian’s CEO and Executive Chair submitted a non-binding proposal to acquire all outstanding shares not already owned by them. A Special Committee is evaluating the offer, and discussions are ongoing. There is no assurance a transaction will materialize, but this development is highly price-sensitive and could significantly impact share values.

Detailed Financial Overview

Q4 2025 vs Q4 2024

Revenue: \$7.96M (Q4 2025) vs \$5.81M (Q4 2024), up 37%
Net Income/Loss: \$(1.82)M Q4 2025 vs \$0.20M Q4 2024
EPS (Diluted): \$(0.06) Q4 2025 vs \$0.01 Q4 2024
Adjusted EBITDA: \$(0.17)M Q4 2025 vs \$0.12M Q4 2024

Full Year 2025 vs 2024

Revenue: \$30.26M (2025) vs \$20.15M (2024), up 50%
Net Loss: \$(2.87)M (2025) vs \$(3.77)M (2024), net loss per share improved to \$(0.09) from \$(0.12)
Adjusted EBITDA: \$0.84M (2025) vs \$0.49M (2024), up 72%
Cost of Revenues: \$14.16M (2025) vs \$7.33M (2024)
R&D Expenses: \$2.92M (2025) vs \$1.44M (2024)
Sales & Marketing: \$6.03M (2025) vs \$4.33M (2024)
General & Administrative: \$9.41M (2025) vs \$12.54M (2024)
Strategic Review & Transaction Expenses: \$1.30M (2025) vs \$0.76M (2024)
Cash Flow from Operations: \$2.89M (2025) vs \$0.28M (2024)
Net Cash Provided by Investing Activities: \$12.94M (2025) vs \$17.29M (2024)
Net Cash Used in Financing Activities: \$(7.52)M (2025) vs \$(19.02)M (2024)
Cash and Equivalents at Year End: \$12.90M (2025) vs \$4.59M (2024)

Balance Sheet Highlights

Total Assets: \$44.13M as of December 31, 2025 (down from \$47.17M in 2024)
Total Liabilities: \$14.35M (2025) vs \$17.12M (2024)
Total Stockholders’ Equity: \$29.78M (2025) vs \$30.05M (2024)
No Preferred Stock outstanding at year-end 2025 or 2024
Convertible Notes: Paid off in 2025, reducing liabilities compared to \$6.7M in 2024

Non-GAAP Measures and Adjustments

Forian provides Adjusted EBITDA as a non-GAAP measure, adjusting for depreciation & amortization, stock-based compensation, interest and investment income, interest expense, gains/losses on investments and debt redemptions, litigation and strategic review expenses, contract termination impacts, and income tax expense.
The company notes that while useful for period-to-period comparisons and internal management decisions, Adjusted EBITDA should not be considered a substitute for GAAP results.

Forward-Looking Considerations

Ongoing Buyout Discussions: The ongoing evaluation of the CEO-led buyout proposal is a major development for shareholders and could significantly affect the share price, depending on the outcome and terms.
Operational Outlook: Forian is focused on expanding its data platform and client base in life sciences, healthcare, and financial services. Continued investment is expected, but cost management remains a priority.
Risks: The company continues to face upstream data supply challenges, industry churn, and the need to renew or replace key data contracts. Litigation and strategic review expenses have also been significant.
Balance Sheet: The company ended the year with a strong liquidity position, no convertible debt, and a solid equity base, supporting ongoing operations and strategic flexibility.

Potential Price-Sensitive Information for Shareholders

CEO-Led Buyout Proposal: The board is actively considering a potentially transformative acquisition offer led by the current CEO and Executive Chair. Any developments, terms, or decisions related to this proposal could have a major impact on Forian’s share price.
Significant Revenue Growth and Improved Adjusted EBITDA: The company’s strong top-line growth and improved operating profitability (on an adjusted basis) may positively influence investor sentiment, even as GAAP losses widened in the fourth quarter.
Reduction in Convertible Debt: The elimination of convertible notes in 2025 reduces financial risk and may improve the company’s credit profile and attractiveness to investors.

Forian’s financial and strategic trajectory remains closely tied to developments in the buyout process and the company’s ability to maintain revenue growth while improving profitability. Shareholders should monitor further announcements from the Special Committee regarding the acquisition proposal and any changes to the company’s operational or financial outlook.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those discussed herein.